Antiviral Drugs on the Treatment of SARS-CoV-2

• Status: Recruiting
• Trial end date: 2021-12-25
• Target enrollment: 0
• Participant gender: All

Summary

Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astana Medical University
• Treatments: Favipiravir; Remdesivir

Criteria

Inclusion Criteria:

main group

• Patients with COVID19 with medium and easy condition disease

• take favipiravir/remdisivir control group

• Patients with COVID19 with medium and easy condition disease

• not take favipiravir/remdisivir

Exclusion Criteria:

• patients younger 18

• severe conditionis